GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Inventories, Other

APM (Aptorum Group) Inventories, Other : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Aptorum Group's other inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Aptorum Group's annual other inventories declined from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.03 Mil) and declined from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($0.00 Mil).


Aptorum Group Inventories, Other Historical Data

The historical data trend for Aptorum Group's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Inventories, Other Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial 0.03 0.04 0.04 0.03 -

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 - - -

Aptorum Group Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Aptorum Group Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.